340B Drug Price Transparency Gains Traction
Executive Summary
A Web site created through a pilot program has helped instill greater confidence among 340B entities on the accuracy of the drug prices they pay, and a bill pending in Congress would ensure price transparency
You may also be interested in...
“Penny Pricing” Guidance Document On Hold Until 340B Office Gets Funding
A long-promised official policy on "penny pricing" for drugs sold to 340B entities is on hold until Congress appropriates funding for the Health Resources and Services Administration's Office of Pharmacy Affairs. Until then, drug manufacturers will need to work on a case-by-case basis with OPA to resolve any pricing issues
“Penny Pricing” Guidance Document On Hold Until 340B Office Gets Funding
A long-promised official policy on "penny pricing" for drugs sold to 340B entities is on hold until Congress appropriates funding for the Health Resources and Services Administration's Office of Pharmacy Affairs. Until then, drug manufacturers will need to work on a case-by-case basis with OPA to resolve any pricing issues
Medicaid AMPs May Include More PBM Discounts, If CMS Can Figure Out How
CMS wants to include a broader array of pharmacy benefit manager price concessions in calculating Medicaid average manufacturer prices for reimbursing outpatient prescription drugs